Company intelligence / Profile preview

Gyeongnam Venture Investment

Changwon, Gyeongsangnam-do, South Korea

Ownership: Private
Development stage: Other

Overview

Gyeongnam Venture Investment (GNVI) is a South Korean venture capital firm founded in 2019, specializing in early-stage investments (1-5M USD) across diverse industries including Biotechnology, Healthcare, Technology, and Manufacturing. The firm manages funds such as the Southeastern Bio Fund ($14.35M) and focuses on startups within the Gyeongsangnam-do region. GNVI has made 16 investments, including in companies like HealthTech Solutions, BioMed Labs, AffyXell (MSC therapies), and Biomatz (microbiome therapeutics).

Industry: Investors

Beyond the preview

Go deeper on Gyeongnam Venture Investment.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gyeongnam Venture Investment.

Explore the full profile